Programmed cell death and cell corpse clearance are an essential part of an organism’s overall health and development. Cell corpses are often engulfed by professional phagocytes such as macrophages. However, in certain tissues, neighboring non-professional cells can also carry out phagocytic functions. Here, we use the Drosophila melanogaster ovary to investigate novel genes required for engulfment by non-professional phagocytes. In the Drosophila ovary, neighboring epithelial cells facilitate the clearance of dying germline cells. We performed an unbiased kinase screen to identify novel proteins and pathways involved in cell clearance in the nurse cell. Several genes identified in this screen were members of the phosphoinositide 3-kinase (PI3K) family. The class II and III PI3Ks are required for nurse cell clearance and acidification during late-stage oogenesis. Class I PI3K is required for progression during engulfment in mid-stage oogenesis. This kinase screen has revealed novel genes for further exploration and investigation. / 2019-02-28T00:00:00Z

La phosphorylation/déphosphorylation des protéines est un mécanisme de signalisation intracellulaire commun. Parmi les kinases végétales, les Mitogen-Activated Protein Kinases (MAPKs) sont impliquées dans de nombreux processus biologiques importants, comme la réponse aux stress biotiques et abiotiques, le développement et la dynamique du cytosquelette. Chez Arabidopsis thaliana et ce malgré de nombreux efforts, les fonctions des kinases impliquées dans les cascades MAPK restent peu inconnues. L'activation des kinases en utilisant des mutations mimant la phosphorylation des sites normalement phosphorylés est une approchequi a fait ses preuves dans le cas de MAP2Ks et a largement contribué à élucider leurs fonctions. Cette stratégie s’est révélée impossible dans le cas des MAPKs, puisque les résidus à muter restent encore à identifier. Pour contourner ce problème, nous avons adapté un crible basé sur la complémentation fonctionnelle d’un mutant MAPK de levure avec des formes aléatoirement mutées de MPK6d’Arabidopsis dans le but d'identifier des mutants présentant une activité constitutive. Nous en avons identifiés plusieurs et avons montré que ces formes constitutivement actives (CA) de MPK6 sont actives sans phosphorylation par les MAP2Ks. Par ailleurs, les mutations des résidus équivalents dans d'autres MAPKs les rendent également hyperactives, ce qui indique que cette stratégie peut être utilisée comme approche générale pour activer les MAPKs afin d’en comprendre les fonctions. L’étude des interactions protéine-protéine et l’analyse des profils dephosphorylation indiquent que les MAPKs CA conservent leur spécificité envers leurs substrats et interacteurs. Comme preuve de concept, nous avons généré des formes actives du MPK4. La MPK4 CA exprimée sous son propre promoteur a parfaitement complémenté le mutant mpk4. La caractérisation des lignées exprimant MPK4 CA confirme le rôle négatif de cette kinase dans les réponses de défense aux pathogènes des plantes que ce soit dans la PTI (PAMP Triggered Immunity) ou dans la ETI (Effector Triggered Immunity). Globalement, ce travail permettra de fournir des informations directes sur les cibles des MAPKs et devrait contribuer à la compréhension globale de la transduction du signal chez les plantes. / Protein phosphorylations and dephosphorylations are common events occurring duringintracellular signaling processes. Among plant kinases, Mitogen-Activated Protein Kinases (MAPKs) are involved in signaling of many important biological processes, including biotic and abiotic stresses, development and cytoskeleton organization. Despite an abundant literature on MAPKs, the exact roles and direct targets of many Arabidopsis thaliana MAPKs are not clear yet. The activation of kinases using phospho-mimicking mutations of the phosphorylated residues was a successful approach in the case of MAP2Ks, helping to elucidate their functions. This strategy failed in the case of MAPKs since the necessary residues to mutate remain unclear. To bypass this problem, we adapted a screen based on the functional complementation of a MAPK yeast mutant with randomly mutated Arabidopsis MPK6 in order to identify the ones mutants showing constitutive activity. We identified several clones and showed that these constitutively active (CA) of MPK6 candidates are indeed active without phosphorylation by MAP2Ks. Interestingly, mutations of the equivalent residues in other MAPKs triggered constitutive activity as well, indicating that this strategy may be used as a general approach to activate MAPKs and identify their functions. Interaction and phosphorylation assays indicatedthat CA MAPKs retain their substrate and interactor specificity. As proof-of-concept, we generated active versions of MPK4. CA MPK4 expressed under itsown promoter successfully complements mpk4 mutant plants. Characterization of CA MPK4 lines further confirmed the negative role of MPK4 in plant pathogen defense responses and its implication in both PTI (PAMP Triggered Immunity) and ETI (Effector Triggered Immunity). Overall, the work will help to provide direct information on all MAPK targets and should be an important contribution to the overall understanding of signal transduction in plants.

Cyclin-Dependent Kinase 11 (CDK11) is a serine/threonine kinase encoded at human locus 1p36.3 by two paralogous genes CDK11A and CDK11B. CDK11 has diverse roles in the regulation of transcription, splicing, apoptosis and mitosis. In proliferating cells, two predominant isoforms are expressed: CDK11p58 and CDK11p110. CDK11p110 is expressed throughout the cell cycle and regulates transcription and splicing. CDK11p58 is expressed at mitosis via IRES-dependent translation; it mediates mitotic progression and faithful chromosome segregation. Loss of Cdk11 in murine models causes early embryonic lethality, demonstrating that CDK11 is essential for normal development. Furthermore, dysregulated CDK11 expression is associated with numerous late-onset disease states, indicating its importance in adult life. In cancer, abnormal expression of CDK11 correlates with poor prognosis in a variety of tumours. Moreover, deletion of the chromosomal region 1p36.3, containing the CDK11 locus, is frequently observed in cancer and has recently been identified in a case of the development disorder, Cornelia de Lange Syndrome (CdLS). This thesis aimed to examine the functions of CDK11 and the impact of their dysregulation in cancer and developmental phenotypes. The initial aim was to investigate the novel role for CDK11 in regulating autophagy in cancer cells; CDK11 depletion causes a marked autophagy phenotype, with accumulation of autophagy protein LC3. I demonstrate that this CDK11-mediated autophagy occurs as a consequence of mitotic dysregulation. Subsequently, I examined the role of autophagy following aberrant mitosis and chromosome missegregation. I show that autophagy is important in the maintenance of aneuploid karyotypes, with loss of autophagy impairing the survival of aneuploid cell populations. I then investigated the effects of CDK11 in regulating cancer cell motility and determined that CDK11 depletion retards cancer cell migration. However, I was unable to identify any failure in cell adhesion or cell polarization to explain this migration phenotype. Subsequently, I interrogated the CDK11 interactome to further characterize the mechanisms through which CDK11 regulates both novel and established functions. This work indicated the involvement of the distinct CDK11 isoforms in pathways that have not previously been reported. This included the interaction of CDK11p110 with ribosomal and spliceosomal proteins during mitosis and the interaction of CDK11p58 with spliceosomal and proteosomal constituents also during mitosis. These findings may provide the foundation for further study. Finally I describe work undertaken to sequence the CDK11 locus in a cohort of CdLS patients, with no known causative genetic mutation, to investigate CDK11A/CDK11B as candidate disease-associated genes. Although no causative mutation in CDK11A or CDK11B was identifying, sequencing of this region indicated NCBI and UCSC genome assemblies of this locus were inaccurate due to the genomic duplication. This has been confirmed by others and corrected in the most recent genome assemblies.

Genome sequencing is emerging as a powerful tool to identify the molecular mechanism of cancer progression. However, the software tools to define genomic and post-genomic mutations are just in its infancy. We have used a novel software algorithm to analyse the cancer genome by DNAseq and expressed cancer genome arising from transcription by RNAseq to define dominant sources of potentially expressed tumour-specific mutations and oncogenic targets. We focus primarily on the rare human pleomorphic sarcoma as a disease of high unmet clinical need but use a range of cancer models to accelerate the development of the pipeline. First, we applied next generation sequencing of whole exomes of tumour tissues and two matched normal tissues (blood and “normal” tumour adjacent tissue) from a small set of patients to define parameters for use of the new software. The approaches identified significant mutations in tumour relative to germline DNA, but also in normal adjacent tissue, relative to normal germline, consistent with known field cancerization. Thus, in setting up the larger sequencing screen in the subsequent set of twenty cancer pleomorphic sarcoma cancer patients, whole exome sequencing was performed on tumour tissue and their matched normal adjacent tissues, rather than germline blood derived DNA, to define truly tumour-specific mutations. This approach provided sets of recurrent non-synonymous mutations in tumour tissue such as a transmembrane protease and suggests potential therapeutic targets for future focus that are highly tumour specific in pleomorphic sarcoma. A major problem with using DNA genomics only to define drugable landscapes in cancer is that the tumour genome is static and the mutations do not reflect the expressed cancer landscape at the time of surgery. Thus, in a smaller subset of patients we also applied shotgun RNAseq to determine the number of expressed mutated genes. We defined within the parameters chosen, from 8-17% of the mutated genome is expressed as defined at the RNA level. However, to our surprise, there were an order of magnitude more RNA mutations that were not DNA encoded suggestive of RNA editing events. Each patient showed elevated RNA edits that were independent of each other suggesting a highly-patient, cancer-specific perturbation in the specificity of the RNA editing machinery. We thus developed a cancer cell model to validate the RNA-editing software and we found we could recapitulate some of the RNA edits observed in clinical tumour tissue, in particular the signalling kinase in the MAP kinase-kinase-kinase-kinase super-family. It was interesting that RNA edits can often cluster in exon-intron boundaries suggesting a link to splicing and allows us to begin to produce “rules” for RNA editing. These data provide future direction to understand the role of RNA editing, as well as DNA encoded mutations, as mutagenic events and possible drugable targets in cancer signalling. Lastly, novel or orphan mutant proteins observed in human cancers, whether from DNA encoded mutant proteins or from RNA-edited driven mutant protein synthesis require new tools and technologies to discover new oncogenic signalling mechanisms. We developed an SBP-tagged affinity purification method in combination with label-free SWATH mass spectrometry to identify a novel binding protein for the gain-of-function mutant protein in a key metastatic gene, ELMO1. This identified an elevated interaction with another oncogenic protein encoded by AGR2 gene and validates this proteomics discovery platform to further advance function of new mutated proteins. In conclusion, we have applied and validated newly emerging software to begin to interrogate cancer tissue from patients of unmet clinical need in order to define new mechanisms of cancer progression and to define possibly new or better drug targets for new therapies. The data identified highly recurrent genome encoded mutations in human pleomorphic sarcoma and a potentially novel, targetable landscape represented by RNA editing driven mutant protein production. This will provide a foundation for future work on making better choices to advance our ability to improve patient management in human pleomorphic sarcoma.

The TAK1 and canonical IKK complexes are the two master protein kinases of the innate immune system that control the production of inflammatory mediators, but the mechanisms by which they are activated in this system are still unclear. In this thesis, I present the research I have carried out to solve these problems. The IKKb component of the canonical IKK complex is required to activate the transcription factors NF-kB and IRF5 and the protein kinase Tpl2, but how IKKβ itself is activated in vivo is still unclear. It was found to require phosphorylation by one or more ‘upstream’ protein kinases in some reports, but by autophosphorylation in others. In the first part of this thesis, I describe my work that has resolved this controversy by demonstrating that the activation of IKKb induced by IL-1 (interleukin-1) or TNF (tumour necrosis factor) in embryonic fibroblasts, or by ligands that activate Toll-like receptors in macrophages, requires two distinct phosphorylation events: first, the TAK1 catalysed phosphorylation of Ser177 and, secondly, the IKKb-catalysed autophosphorylation of Ser181. The phosphorylation of Ser177 by TAK1 is a priming event required for the subsequent autophosphorylation of Ser181, which enables IKKk to phosphorylate exogenous substrates. I also present genetic evidence which indicates that the IL-1-stimulated, LUBAC (linear ubiquitin chain assembly complex)-catalysed formation of Met1-linked/linear ubiquitin (Met1-Ub) chains and their interaction with the NEMO (NF-kB essential modulator) component of the canonical IKK complex permits the TAK1-catalysed priming phosphorylation of IKKb at Ser177 and IKKa at Ser176. These findings may be of general significance for the activation of other protein kinases. The activation of the TAK1 complex by inflammatory stimuli is thought to be triggered by the binding of Lys63-linked ubiquitin chains to the TAB2 or TAB3 components of the TAB1-TAK1-TAB2 and TAB1-TAK1-TAB3 complexes. In the second part of the thesis I tested whether this broadly accepted model was correct by knocking out the genes encoding TAK1 and its regulatory subunits TAB1, TAB2 and TAB3 by CRISPR/Cas9 gene-editing technology, alone and in combination, in an IL-1 receptor expressing human cell line. These genetic studies led me to discover that the IL-1-dependent activation of TAK1 occurs by two different mechanisms. The first, involves the previously described interaction of Lys63-linked ubiquitin chains with TAB2 and TAB3, while the second can take place in the complete absence of TAB2 and TAB3. The second mechanism, which involves activation of the TAB1-TAK1 heterodimer is more transient than the first, but is sufficient for the IL-1-dependent transcription of immediate early genes (A20, IkBa). I show that the activation of the TAB1-TAK1 complex requires the expression of the E3 ubiquitin ligase TRAF6 and the TRAF6-generated formation of Lys63-linked ubiquitin chains, which leads to the phosphorylation of TAK1 at Thr187 and activation. However, neither TAB1 nor TAK1 bind directly to Lys63-linked ubiquitin chains. I identify one novel IL-1-dependent phosphorylation site on TAB1 and two on TAK1 and propose that Lys63-linked ubiquitin chains activate an as yet unidentified protein kinase, which phosphorylates one or more of the novel phosphorylation sites on the TAB1-TAK1 heterodimer inducing a conformational change that permits TAK1 to autophosphorylate Thr187.

Le réseau de signalisation qui répond à l’insuline et aux nutriments est conservé chez les métazoaires, où il joue un rôle central dans le contrôle du métabolisme et de la croissance. Les nutriments assimilés sont soit directement utilisés pour la croissance tissulaire, soit stockés principalement sous forme de triglycérides. Chez la drosophile, l’activation de ce réseau de signalisation dans le corps gras, un organe qui remplit à la fois les fonctions hépatiques et destockage, induit une augmentation du stockage de lipides sous forme de nombreuses gouttelettes lipidiques (LDs). A l’inverse, la carence alimentaire se traduit par une augmentation de la taille des LDs et une diminution de lipides stockés. La kinase TOR (TargetOf Rapamycine) et son substrat S6 Kinase (S6K) jouent un rôle central dans cette régulation.Chez la drosophile, ces 2 kinases (dTOR et dS6K) contrôlent les aspects autonome-cellulaireset hormonaux de la croissance. En dépit de nombreuses études sur divers organismes modèles,destinées à comprendre les mécanismes régulateurs de S6K, rien n’est connu à ce jour sur lecontrôle de sa dégradation.Nous avons utilisé une banque de lignées exprimant des ARN interférant (RNAi) contre unegrande quantité de gènes de la drosophile, pour réaliser 3 des cribles génétiques destinés à identifier de nouveaux régulateurs du métabolisme et de la croissance. Dans le premier crible,les RNAi ont été induits dans la glande prothoracique, siège de la production de l’hormonestéroïde ecdysone connue pour réguler la croissance et les étapes du développement, souscontrôle de la nutrition et de la signalisation dTOR. Sur 7000 gènes criblés, 620 ont étéidentifiés comme nécessaire à la production d’ecdysone. Dans le second crible, nous avonsexprimé les RNAi de 4000 gènes dans le corps gras pour rechercher ceux qui induisaient uneaugmentation de la taille des LDs. L’objectif était d’identifier des gènes impliqués dans la réponse à la carence alimentaire, et nous avons ainsi retenu 24 candidats intéressants. Le troisième crible représente la majeure partie du travail de thèse, où nous avons criblé les RNAi susceptibles de modifier un phénotype de croissance induit par dS6K. Sur 7000 gènes testés,nous en avons retenu 45 qui ont ensuite été utilisés pour générer un diagramme d’interaction en utilisant les informations disponibles dans les banques de données. Les candidats les plus intéressants ont ensuite été analysés en culture de cellules pour identifier ceux qui régulent l’activité de dS6K et ceux qui régulent sont niveau d’expression. Parmi ces derniers, nousavons identifié le gène codant pour Archipelago (Ago), connue pour contrôler la dégradationrégulée des protéines-cibles au niveau du protéasome. Nous avons réalisé de nombreusesexpériences qui montrent que ago et dS6K interagissent génétiquement. En outre, il est indiquédans les banques de données que ces protéines interagissent entre elles par la technique des 2-hybrides en levure. Tous ces résultats révèlent que Ago régule la dégradation de dS6K, etposent les premières pierres de ce niveau de régulation. / The evolutionary conserved insulin and nutrient signaling network regulates growth andmetabolism. Nutrients are directly utilized for growth or stored, mostly as triglycerides. InDrosophila, activation of insulin/nutrient signaling in the fat body (the fly equivalent of liverand adipose tissue), causes an increase in fat stores composed of several small-size lipiddroplets (LDs). Conversely, fasting produces an increase in LD size and a decrease in fatcontents. The TOR kinase and its substrate S6 kinase (S6K) play a central role in this response,and particularly in Drosophila, they have been shown to orchestrate cell-autonomous andhormone-controlled growth. However, despite extensive research studies on different modelorganisms (mouse, fly, worm) to decipher the molecular and physiological functions of S6K,nothing is known about how its degradation is regulated.Taking advantage of the inducible RNA interfering (RNAi) library from NIG (Japan), we haveperformed three genetic screens to identify novel regulators of steroidogenesis, lipidmetabolism and dS6K-dependent growth. First, RNAi lines were screened in the ring gland; anorgan that controls the progression of the developmental steps by producing the steroidhormone ecdysone. Out of 7,000 genes screened, 620 positive candidates were identified toproduce developmental arrest and/or overgrowth phenotypes. Then, we challenged 4,000 genesby RNAi screening able to recapitulate the larger sized LD phenotype as obtained uponstarvation, leading to the identification of 24 potential candidates. Finally, the RNAi lines werescreened for their ability to enhance a growth phenotype dependent of the Drosophila S6K(dS6K). Out of 7,000 genes screened, 45 genes were identified as potential negative regulatorsof dS6K. These genes were further used to design a novel protein-protein interaction networkcentered on dS6K through the available data from yeast-2-hybrid (Y2H) assay. The most potentinteractors were then analyzed by treatment of cultured S2 cells with the corresponding doublestrand RNA (dRNA). Western blotting thus, allowed us to discriminate between the geneproducts that regulate dS6K levels versus those that regulate its phosphorylation, as a hallmarkfor its kinase activity. Interestingly, archipelago (ago), which encodes a component of an SCFubiquitinligase known to regulate the degradation of dMyc, Cyclin E and Notch, was identifiedas a negative regulator of dS6K-dependent growth. Based on the Y2H available data showingthat Ago and dS6K interact each other and the presence of a putative Ago-interaction motif indS6K, we hypothesized that Ago causes an ubiquitin-mediated degradation of dS6K. Ourmolecular data showed that loss of ago caused an elevated level of dS6K, which confirms arole of Ago in controlling dS6K degradation. Altogether our findings emphasize the importanceof the saturating screening strategies in Drosophila to identify novel regulators of metabolicand signaling pathways.

Despite the global effort to discover and improve ways to detect, treat, and monitor cancer, it still remains the second leading cause of death in the United States and poses a major health and economic burden worldwide. While traditional treatments like surgery, chemotherapy, radiation therapy, and hormone therapy have been successful and have decreased cancer mortality, cancer incidence in all sites continues to rise. Consequently, there is an immediate need to find new therapeutics for the treatment of cancer. In recent years, and with the continuing push towards personalized medicine, cancer biomarkers have become crucial to detect, treat, and monitor cancer. Thymidine kinase 1 (TK1) has been identified as a cancer biomarker with diagnostic, prognostic, and therapeutic potential. TK1 is a nucleotide salvage pathway enzyme responsible for maintaining a balance in the cell nucleotide pool and providing the cell with thymidine monophosphate, which upon further phosphorylation is incorporated into DNA during cell replication. TK1 has been found to be upregulated in the serum of cancer patients. Serum TK1 (sTK1) has been used as an early diagnostic and prognostic biomarker in many types of cancer and has been shown to be a better proliferation biomarker than Ki67. In this dissertation, we described the characterization of TK1 as a cancer biomarker that associates with the plasma membrane of hematological malignancies such as Burkitt's lymphoma, acute lymphoblastic leukemia, acute promyelocytic leukemia, acute T cell lymphoma, and solid malignancies such as lung, breast, and colon cancer. We also describe the different oligomeric TK1 forms that are found on the cell membrane and show that membrane TK1 has activity. We assess the clinical relevance of TK1 in all these malignancies, looking at tissue expression as well as gene expression from patients from The Cancer Genome Atlas database. We find that TK1 is not expressed on the surface of normal cells, whether they are proliferating or not, making TK1 a unique cancer biomarker, with the potential to be used in targeted therapy. We also find that TK1 expressed on the surface may be involved in the invasion potential of cancer cells. The knowledge gained from this study will help researchers working in clinical research and cancer immunotherapeutics to potentially use TK1 as a biomarker and cancer target, and thus providing another weapon against cancer. In this dissertation, we described the characterization of TK1 as a cancer biomarker that associates with the plasma membrane of hematological malignancies such as Burkitt's lymphoma, acute lymphoblastic leukemia, acute promyelocytic leukemia, acute T cell lymphoma, and solid malignancies such as lung, breast, and colon cancer. We also describe the different oligomeric TK1 forms that are found on the cell membrane and show that membrane TK1 has activity. We assess the clinical relevance of TK1 in all these malignancies, looking at tissue expression as well as gene expression from patients from The Cancer Genome Atlas database. We find that TK1 is not expressed on the surface of normal cells, whether they are proliferating or not, making TK1 a unique cancer biomarker, with the potential to be used in targeted therapy. We also find that TK1 expressed on the surface may be involved in the invasion potential of cancer cells. The knowledge gained from this study will help researchers working in clinical research and cancer immunotherapeutics to potentially use TK1 as a biomarker and cancer target, and thus providing another weapon against cancer.

Cancer, a disease characterized by dangerous and uncontrollable cell growth and division, is often caused by abnormal activity levels of both tumor inducing and tumor suppressing proteins. One protein that has been shown to promote cancer progression when mutated or dysregulated is tyrosine kinase Src, which phosphorylates proteins involved in cell morphology, motility, proliferation, and survival pathways. Previous studies of Src have found two conformational features (the αC-helix and activation loop) that determine whether the enzyme is in its active or inactive state, and different types of kinase inhibitors bind these different conformations of Src. In order to investigate the efficacy of the three most common classes of kinase inhibitors against Src kinase mutants, a high throughput scan of a library of single amino acid Src mutants treated with various kinase inhibitors was performed. This experiment resulted in preliminary relative activity levels of all Src mutants in the library along with how these activity levels changed in the presence of each of the three inhibitors. This study investigates specific Src mutants’ activity levels and inhibitor sensitivity seen in the high throughput scan through individual validation experiments. Site-directed mutagenesis was used to generate these mutants, and then a functionality assay was used to determine the activity levels of each mutant in comparison to wildtype Src. The relative activity levels in the no inhibitor condition of the four Src mutants used in this study correlated closely with the expected activity levels seen in the high throughput scan. Furthermore, Src mutant V331E demonstrated the same differential resistance to two different kinase inhibitors that was seen in the inhibitor specific high throughput scans. This mutant appeared to be sensitive to one inhibitor and resistant to another in both the high throughput scans and the individual validation experiment. Mutation V331E’s proximity to the conformation determining αC-helix may explain this differential resistance. Further studies are necessary to investigate the precise structural changes in Src that occur as a result of this mutation in order to understand the differential resistance seen in this mutant.

Chronische Aktivierung von b-Adrenorezeptoren (b-ARs) durch Katecholamine ist ein Stimulus für kardiale Hypertrophie und Herzinsuffizienz. Ebenso führt die Expression von b1-ARs oder Gas-Proteinen in genetisch modifizierten Mäusen zu Hypertrophie und Herzinsuffizienz. Allerdings führt die direkte Aktivierung dem Gas nachgeschalteten Komponenten des b-adrenergen Signalwegs wie z.B. die Aktivierung der Adenylylcyclase (AC) oder der Proteinkinase A (PKA) nicht im signifikanten Ausmaß zur Herzhypertrophie. Diese Ergebnisse deuten darauf hin, dass zusätzlich zu dem klassischen Signalweg, auch weitere durch Gas-Proteine aktivierte Komponenten in die b-adrenerg vermittelte Hypertrophieentwicklung involviert sind. Interessanterweise wurde vor kurzem ein hypertropher Signalweg beschrieben, der eine direkte Involvierung von Gbg-Untereinheiten bei der Induktion von Herzhypertrophie durch die extrazellulär-regulierten Kinasen 1 und 2 (ERK1/2) zeigt: Nach Aktivierung Gaq-gekoppelter Rezeptoren binden Gbg-Untereinheiten an die aktivierte Raf/Mek/Erk Kaskade. Die Bindung der freigesetzten Gbg-Untereinheiten an Erk1/2 führt zu einer Autophosphorylierung von Erk1/2 an Threonin 188 (bzw. Thr208 in Erk1; im folgenden ErkThr188-Phosphorylierung genannt), welche für die Vermittlung kardialer Hypertrophie verantwortlich ist. In dieser Arbeit konnte nun gezeigt werden, dass auch die Aktivierung von b-ARs in Mäusen sowie von isolierten Kardiomyozyten zur Induktion von ErkThr188-Phosphorylierung führt. Darüberhinaus führte die Überexpression von Erk2 Mutanten (Erk2T188S und Erk2T188A), die nicht an Threonin 188 phosphoryliert werden können, zu einer deutlich reduzierten Hypertrophieantwort von Kardiomyozyten auf Isoproterenol. Auch die kardiale Expression der Erk2T188S Mutante im Mäusen verminderte die Hypertrophieantwort auf eine 2-wöchige Isoproterenol-Behandlung deutlich: Die linksventrikuläre Wanddicke, aber auch interstitielle Fibrose und Herzinsuffizienzmarker wie z.B. BNP waren signifikant reduziert. Weiterhin konnte in dieser Arbeit gezeigt werden, dass tatsächlich ein Zusammenspiel von Ga und Gbg-vermittelten Signalen zur Induktion von ErkThr188-Phosphorylierung und damit zur Induktion von b-adrenerg vermittelter Hypertrophie notwendig ist. Während die Hemmung von Gbg-Signalen mit dem C-Terminus der GRK2 oder die Hemmung von Adenylylzyklase eine ErkThr188-Phosphorylierung und eine Hypertrophieantwort nach Isoprenalingabe effektiv reduzierten, führt die alleinige Aktivierung von Adenylylzyklase nicht zu einer Hypertrophieantwort. Diese Ergebnisse könnten bei der Entwicklung neuer möglicher therapeutischen Strategien zur Therapie b-adrenerg induzierter Herzhypertrophie und Herzinsuffizienz helfen. / b-adrenergic receptors (b-ARs) participate strongly in the development of cardiac hypertrophy and human heart failure. Stimulation of b-adrenergic receptors with catecholamines as well as cardiac overexpression of b1-ARs or of Gas-proteins in transgenic mice induces cardiac hypertrophy. However, direct activation of their downstream targets, such as adenylyl cyclase (AC) or protein kinase A do not promote a significant degree of cardiac hypertrophy. These findings suggest that additional events may occur and that these events require Gas-protein activation. A hypertrophic pathway involving Gaq-protein coupled receptors has recently been described. Upon activation of Gaq-coupled receptors Gbg-subunits are released from Gaq and bind directly to the activated Raf/Mek/Erk cascade. Direct interaction between bg-subunits and activated Erk1/2 leads to an additional autophosphorylation of Erk2 at threonine 188, which mediates cardiac hypertrophy. Murine hearts, as well as isolated cardiomyocytes present an increase in Erk2Thr188-phosphorylation upon b-AR activation. Similarly overexpression of phosphorylation deficient Erk2 mutants (Erk2T188S and Erk2T188A) reduces b-AR mediated cardiomyocyte hypertrophy. Increase in left ventricular wall thickness, fibrosis and up-regulation of natriuretic peptide synthesis, which are physiological features for cardiac hypertrophy, are strongly inhibited in transgenic mice with a cardiac expression of Erk2T188S after two weeks of sustained isoproterenol treatment. It could further be shown in this work that b-AR mediated cardiac hypertrophy requires two distinct pathways initiated by Gs-protein activation: the canonical phosphorylation of Erk1/2 via adenylyl cyclase and the direct interaction of released bg-subunits with activated Erk1/2. Coincidence of both events leads to Erk2Thr188-phosphorylation, which activates then different transcription factors responsible for cardiac hypertrophy. Sequestration of bg-subunits by overexpression of the C-terminus of GRK2 bark-ct and inhibition of adenylyl cyclase efficiently reduced the hypertrophic response to isoproterenol, whereas direct activation of AC by forskolin failed to induce Erk2Thr188-phosphorylation and cardiomyocyte hypertrophy. These findings may help to develop new therapeutic strategies for the prevention of cardiac hypertrophy and maladaptive remodeling of the heart.

Die Mechanismen in einer Zelle, die die Genexpression und somit den Stoffwechsel, das Wachstum und das gesamte Zellverhalten steuern, sind ebenso bedeutsam für das Verständnis der grundlegenden Biologie einer lebenden Zelle wie für die Vorgänge der Krebsentstehung. Dabei bilden hochvernetzte, und strikt regulierte Signaltransduktionswege die Basis für ein belastbares und zugleich hochflexibles regulatorisches Netzwerk. Die Störung solcher Signalkaskaden kann zum einen ursächlich aber auch modifizierend auf die Bildung von Tumoren wirken. Die von Rezeptortyrosinkinasen (RTK) und RAS abhängigen Signalwege, die zur Aktivierung von AKT und ERK1/2 führen, sind hierbei von besonderem Interesse für die Entstehung des malignen Melanoms. Mutationen in Komponenten dieser Wege (z.B. NRAS, BRAF oder PTEN), die die Signalstärke erhöhen kommen in Melanomen sehr häufig vor. Im ersten Teil dieser Arbeit wurden die unterschiedlichen und vielfältigen Funktionen von MKP2, einem Feedbackregulator des ERK1/2-Weges, unter verschiedenen zellulären Rahmenbedingungen, untersucht. Des Weiteren wird eine Funktion des zum AP1-Komplex gehörenden FOSL1, einem unter transkriptioneller Kontrolle des ERK1/2-Weges stehendem Transkriptionsfaktors, hinsichtlich der Steuerung der Zell-Proliferation gezeigt. Weiterhin habe ich Aspekte der direkten pharmakologischen Inhibition des ERK1/2-Weges hinsichtlich ihres Effekts auf die Auslösung von Apoptose untersucht. Aufgrund der Häufigkeit von Mutationen in Genen, die für Proteine des ERK1/2-Weges kodieren (z.B. NRASQ61K, BRAFV600E), gilt die Inhibition dieses Signalwegs als vielversprechende Strategie zur Behandlung des Melanoms. Auch wenn klinische Studien, die Inhibitoren für MEK oder RAF als Einzelmedikamente verwenden, bei mehrmonatiger Behandlung sehr erfolgreich sind, konnten so keine langfristigen Erfolge erzielt werden. Aus diesem Grund werden nun Kombinationstherapien, die einen Inhibitor des ERK1/2-Weges und eine weitere Form der Therapie kombinieren, untersucht. Der zweite Teil dieser Arbeit beschreibt, dass der spezifische MEK Inhibitor PD184352 Melanomzellen vor der Apoptosewirkung von Cisplatin schützen kann. Einzelbehandlung mit Cisplatin führt hierbei zur Akkumulation von DNA Schäden, die wiederum Caspase-abhängig Apoptose induzieren. Zusätzliche Anwendung des MEK Inhibitors verringerte jedoch in einigen Zelllinien das Potential von Cisplatin, Apoptose auszulösen. Diese Zellen zeigten eine verstärkte Aktivierung der Serin/Threonin-KInase AKT nach MEK Inhibition. Diese AKT Aktivierung führte zur Inaktivierung der FOXO Transkriptionsfaktoren, was wiederum die Expression des pro-apoptotischen BH3-only Proteins PUMA verringerte. PUMA selbst ist ein wichtiger Bestandteil der Apoptose Maschinerie, die durch Cisplatin aktiviert wird. Die im Rahmen dieser Arbeit erhaltenen Befunde deuten darauf hin, dass RTKs, im besonderen EGFR, bei diesem Crosstalk eine Rolle spielen. Diese Ergebnisse zeigen, dass die Inhibition des RAS/RAF/MEK/ERK Signalweges im Melanom nicht zwangsläufig von Vorteil sein muss, falls die Zellen gleichzeitig mit einem genotoxischen Medikament behandelt werden. Hier kann sie sogar die Überlebensfähigkeit von Melanomzellen unter Apoptose induzierenden Bedingungen verbessern. / The mechanisms that enable cells to regulate their gene expression and thus their metabolism, proliferation or cellular behaviour are not only important to understand the basic biology of a living cell, but are also of crucial interest in cancerogenesis. Highly interwoven and tightly regulated pathways are the basis of a robust but also flexible regulatory network. Interference with these pathways can be either causative for tumorigenesis or can modify its outcome. The receptor tyrosine kinase (RTK) and RAS dependent pathways leading to AKT or ERK1/2 activation are of particular interest in melanoma. These signaling modules are commonly activated by different mutations that can be found in various pathway components like NRAS, BRAF or PTEN. The first part of this work deals with the diverse and versatile functions of the ERK1/2 pathway feedbackregulator MKP2 in different cellular, melanoma relevant settings. In addition, a functional role of the AP1-complex member FOSL1, an ERK1/2 transcriptional target being implicated in the regulation of proliferation, is demonstrated. Secondly, aspects of direct pharmacological inhibition of the ERK1/2 pathway with regard to the induction of apoptosis have been analysed. Due to the high frequency of melanoma related mutations occurring in the RAS/RAF/MEK/ERK pathway (e.g. NRASQ61K, BRAFV600E), inhibition of this signaling cascade is deemed to be a promising therapeutic strategy for the treatment of malignant melanoma. However, although in clinical trials mono-therapeutic treatment with MEK- or RAF inhibitors was successful in the short run, it failed to show satisfactory long-lasting effects. Hence, combination therapies using a MAPK pathway inhibitor and an additional therapy are currently under investigation. I was able to demonstrate that inhibition of MEK using the highly specific inhibitor PD184352 can have a protective effect on melanoma cells with regard to their susceptibility towards the apoptosis inducing agent cisplatin. Single application of cisplatin led to strong DNA damage and the induction of caspase-dependent apoptosis. Additional administration of the MEK inhibitor, however, strongly reduced the apoptosis inducing effect of cisplatin in several melanoma cell lines, These cells displayed an increased activation of the serine/threonine kinase AKT after MEK inhibition. This AKT activation concomitantly led to the phosphorylation of FOXO transcription factors, attenuating the cisplatin induced expression of the BH3-only protein PUMA. PUMA in turn was important to mediate the apoptosis machinery after cisplatin treatment. My results also indicate a participation of RTKs, in particular EGFR, in mediating MEK inhibitor induced activation of AKT. These results demonstrate that inhibition of the RAS/RAF/MEK/ERK signaling pathway in melanoma cell lines does not necessilary have favourable effects in a cytotoxic co-treatment situation. Instead, it can even enhance melanoma survival under pro-apoptotic conditions.